Exelixis Aktie

Exelixis ab 0 Euro bei Finanzen invest ordern (zzgl. Spreads)

WKN: 936718 / ISIN: US30161Q1040

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
<
Aktion
Portfolio
Watchlist
>
16.11.2026 22:32:02

Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything

Exelixis (NASDAQ:EXEL) has crushed the broader market over the past five years. It has done so mostly thanks to Cabometyx, a cancer medicine that has been its best-selling drug for years. However, things could change for the biotech by the next decade. Exelixis could start facing generic competition for Cabometyx by 2030. Can the company overcome this patent cliff? The answer largely depends on its leading pipeline candidate.

Image source: Getty Images.

Exelixis's strategy in the past has been to develop cancer medicines that target areas of high unmet medical need. That's what it did with Cabometyx. This medicine became the first in renal cell carcinoma (RCC, a type of kidney cancer) to demonstrate statistically significant improvements in three efficacy endpoints: progression-free survival, objective response rate, and, most importantly, overall survival. Cabometyx became a leading medicine in RCC as a result.

Continue reading

Analysen zu Exelixis Inc.

mehr Analysen
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Exelixis Inc. 60,75 -2,72% Exelixis Inc.